labstyle innovations corp (DRIO) Key Developments
Labstyle Innovations Corp. Signs Partnership Agreement with HMO
Jan 22 15
LabStyle Innovations Corp. reported that it has signed a partnership agreement with HMO; Maccabi Healthcare to implement its comprehensive Dario digital suite for patients and professionals remote proactive care. The agreement with MOMA represents an additional channel of revenue stream for Dario. This channel for revenues indicates the huge potential available in the Dario digital health solution which is based on software licensing and added value services with HMOs and other strategic partners worldwide. The Dario application for MOMA is a proprietary customized diabetes management solution that enables remote treatment for diabetes aiming to improve the overall outcomes for patients leveraging mHealth technology for effective engagement of health care professionals. Through the agreement Maccabi Healthcare will be subscribing to Dario; a cutting edge diabetes management solution that includes an online diabetes solution together with the Dario smart meters for an advanced service they call MOMA. Through MOMA, Maccabi will provide chronic patients a service of advanced multi-disciplinary support and care through a national call center in coordination with the client's primary physician and other community-based resources. Each MOMA member with diabetes will receive their own Dario smart meter for managing and monitoring their diabetes in order to enable the caretakers at the call centers a direct online view and proactive communication over the Dario mobile platform.
LabStyle Innovations Corp. Announces Executive Changes
Jan 8 15
LabStyle Innovations Corp. announced that Zvi Ben-David will be joining as the company's new chief financial officer, treasurer and secretary effective immediately. LabStyle also announced that Gadi Levin, the current chief financial officer will remain in the role of advisor and business development consultant for at least the first half of 2015 as Mr. Ben-David transitions to his new role. Among his previous roles, he served as corporate vice president and chief financial officer of Given Imaging Ltd. Following his tenure at Given, Mr. Ben-David served as chief financial officer of Ultrashape Medical Ltd. Recently, Ben-David has been an independent medical device entrepreneur and investor.
LabStyle Innovations Corp. Appoints Peter Kash and Hila Karah to the Board of Directors
Nov 24 14
LabStyle Innovations Corp. announced that Dr. Peter Kash and Ms. Hila Karah have been appointed to serve on the company's Board of Directors. Dr. Kash and Ms. Karah bring significant experience in commercialization, finance and corporate governance of life science companies to LabStyle's board. Ms. Karah is expected to serve on the Compensation and Nominating Committees of the board. Dr. Kash and Ms. Karah are the designated appointees of Dicilyon Consulting and Investment Ltd. Dr. Kash currently serves as Executive Chairman of iOS app developer Time Flash LLC. Ms. Karah is an independent business consultant and an investor in several high-tech, biotech and Internet companies.
LabStyle Innovations Corp. Announces Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2014
Nov 14 14
LabStyle Innovations Corp. announced unaudited consolidated earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company reported net loss as reported of $6,333,000 against $3,471,000 a year ago. LBITDA was $2,404,000 against $2,974,000 a year ago. NON-GAAP adjusted LBITDA was $2,081,000 or $0.21 per share against $2,231,000 or $0.55 per share a year ago. Operating loss was $2,507,000 against $3,238,000 a year ago. Net loss was $3,077,000 or $0.66 basic and diluted per share, compared to $3,471,000 or $0.85 per share basic and diluted a year ago. The non-GAAP adjusted loss, for the third quarter of 2014 was approximately $2,081,000, or $0.21 per share, compared with a non-GAAP adjusted loss for the third quarter of 2013 of approximately $2,231,000, or $0.55 per share.
For the nine months, the company reported net loss as reported of $12,571,000 against $13,985,000 a year ago. LBITDA was $8,317,000 against $9,332,000 a year ago. NON-GAAP adjusted LBITDA was $6,795,000 or $1.10 per share against $5,728,000 or $1.61 per share a year ago. Operating loss was $8,778,000 against $9,910,000 a year ago. Net loss was $9,315,000 or $2.23 diluted per share, compared to $13,985,000 or $3.95 per share diluted a year ago. The non-GAAP adjusted loss for the first nine months of 2014 was approximately $6,795,000, or $0.10 per share, versus a non-GAAP adjusted loss of approximately $5,728,000, or $1.61 per share, in the corresponding period in 2013. The company used approximately $6,168,000 in cash to fund operating activities during the first nine months of 2014.
Shetron Ltd. Announces Consolidated Unaudited Earnings Results for Second Quarter and Six Months Ended June 30, 2014
Aug 15 14
LabStyle Innovations Corp. announced consolidated unaudited earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported LBITDA of $3,443,000, NON-GAAP adjusted LBITDA of $2,753,000, operating loss of $3,603,000, net loss of $3,254,000 or $0.15 diluted per share, compared to the LBITDA of $3,400,000, NON-GAAP adjusted LBITDA of $2,251,000, operating loss of $3,596,000, net loss of $5,286,000 or $0.29 diluted per share, for the same quarter a year ago.
For the year to date, the company reported LBITDA of $5,913,000, NON-GAAP adjusted LBITDA of $4,714,000, operating loss of $6,271,000, net loss of $6,238,000 or $0.29 diluted per share, compared to the LBITDA of $6,358,000, NON-GAAP adjusted LBITDA of $3,497,000, operating loss of $6,672,000, net loss of $10,513,000 or $0.63 diluted per share, for the same period a year ago.